Skip to main content

Clinical Trials Using Fluoropyrimidine

Review the clinical trials studying fluoropyrimidine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 182

Using Cancer Cells in the Blood (ctDNA) to Determine the Type of Chemotherapy that will Benefit Patients who Have Had Surgery for Colon Cancer, (CIRCULATE-NORTH AMERICA)
Status: Active
Location: 999 locations
mFOLFIRINOX versus mFOLFOX with or without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Status: Active
Location: 688 locations
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Status: Active
Location: 438 locations
Studying Chemotherapy with or without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Status: Active
Location: 266 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 276 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 211 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 113 locations
Testing Chemotherapy versus Chemotherapy plus Radiotherapy Prior to Limited Surgery for Early Rectal Cancer
Status: Active
Location: 99 locations
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Status: Active
Location: 76 locations
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy versus Standard of Care Chemotherapy Alone for Patients with Unresectable Colorectal Liver Metastases: The PUMP Trial
Status: Active
Location: 57 locations
Testing the Addition of Paclitaxel Administered into the Abdominal Cavity Combined with Chemotherapy for Patients with Gastric Cancer Spread to the Abdominal Cavity, STOPGAP II Trial
Status: Active
Location: 44 locations
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Status: Active
Location: 36 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 25 locations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Status: Active
Location: 20 locations
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Status: Active
Location: 20 locations
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Status: Active
Location: 22 locations
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Status: Active
Location: 16 locations
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Status: Active
Location: 16 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 17 locations
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 17 locations
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Status: Active
Location: 15 locations
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Status: Active
Location: 18 locations
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Status: Active
Location: 14 locations
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Status: Active
Location: 13 locations
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Status: Active
Location: 14 locations